The Early Results of Helicobacter Pylori Eradication Therapy for Patients with Chronic Immune Thrombocytopenic Purpura

Murat Pekgöz*¹ and Ridvan Ali²

Received: December 06, 2018;   Published: December 14, 2018

DOI: 10.26717/BJSTR.2018.12.002214

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Background: Immune thrombocytopenic purpura is an autoimmune disease caused by excessive destruction of circulating platelets and characterized by temporary or permanent low platelet count and increased risk of bleeding. Helicobacter pylori can result in various clinical manifestations such as chronic atrophic gastritis, peptic ulcer, gastric cancer, and primary gastric B cell lymphoma. Helicobacter pylori infection has been associated with immune thrombocytopenic purpura, and potential mechanisms have been suggested to increase platelet count after bacterial eradication. We aimed to investigate the association between immune thrombocytopenic purpura and Helicobacter pylori. In addition to reveal improvement platelet count after eradication therapy.

Methods: A total of 85 patients with a diagnosis of immune thrombocytopenic purpura were included in the study. A Urea breath test was conducted. The patients with positive test results underwent standard primary eradication therapy. Two months after eradication therapy, patients were evaluated for Helicobacter pylori infection status and platelet response using the control urea breath test.

Results: The urea breath test was positive in 63.5 % of patients. In 21 of 35 patients with eradication there was a significant increase in platelet count after therapy and the rate platelet response was 60%.

Conclusion: Although Helicobacter Pylori eradication therapy is not currently a primary care option for the treatment of immune thrombocytopenic purpura, it may be considered as an alternative treatment option in unresponsive patients.

Keywords :Immune Thrombocytopenic Purpura; Helicobacter Pylori; Platelet Recovery; Eradication Therapy